Table 3.
Patient characteristics of the propensity-score matched cohort.
| Total (%) | Gefitinib/erlotinib | Afatinib | p-value | |
|---|---|---|---|---|
| N = 412 | n = 206 | n = 206 | ||
| Age ⩾65 years | 271 (65.8) | 138 (66.9) | 133 (64.5) | 0.678 |
| ECOG PS 0–1 | 364 (88.3) | 179 (86.9) | 185 (89.8) | 0.443 |
| Gender | ||||
| Male | 147 (35.7) | 73 (35.4) | 74 (35.9) | 1.000 |
| Current/ex-smoker | 85 (20.6) | 47 (22.8) | 38 (18.4) | 0.330 |
| Histology | ||||
| Adenocarcinoma | 405 (98.3) | 203 (98.5) | 202 (98.1) | 1.000 |
| Others | 7 (1.7) | 3 (1.5) | 4 (1.9) | |
| EGFR mutation | ||||
| L858R | 240 (58.3) | 118 (57.3) | 122 (59.2) | 0.764 |
| 19deletion | 172 (41.7) | 88 (42.7) | 84 (40.8) | |
| Disease stage | ||||
| IIIB | 30 (7.3) | 15 (7.3) | 15 (7.3) | 1.000 |
| IV | 382 (92.7) | 191 (92.7) | 191 (92.7) | |
| Site of metastasis | ||||
| Brain | 152 (36.9) | 79 (38.3) | 73 (35.4) | 0.610 |
| Liver | 53 (12.9) | 25 (12.1) | 28 (13.6) | 0.769 |
ECOG PS, Eastern Cooperative Oncology Group performance status.